Ikena Oncology Gets Fast Track Designation for IK-930 Mesothelioma Treatment

By Chris Wack

Ikena Oncology Inc. said the U.S. Food and Drug Administration has granted Fast Track designation for IK-930 for patients with unresectable NF2-deficient malignant pleural mesothelioma.

Fast Track designation granted by the FDA facilitates the development and expedites the review of drugs intended to treat serious or life-threatening diseases.

Earlier in 2022, the FDA granted IK-930 Orphan Drug designation, which supports development of drugs for rare disorders, as a potential novel therapeutic option for patients with malignant pleural mesothelioma.

IK-930 is currently being studied in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors.

Ikena shares were up 12%, to $3.88, in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

June 22, 2022 07:53 ET (11:53 GMT)

Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Aug 2024 to Sep 2024